AIM - AIM Immunotech advances Phase 1 Ampligen study in COVID-19; reports no serious adverse events

AIM ImmunoTech (AIM) has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.No serious adverse events ((SAE)) were reported and the study will proceed with enrollment into Cohort 3. The study protocol calls for a total of 40 healthy subjects to receive repeated administration of either Ampligen or a placebo.Subjects in Cohort 1 received 75 ?g of Ampligen, while subjects in Cohort 2 received 200 ?g of Ampligen.The dosage will escalate to 500 ?g in Cohort 3, with the highest level of 1250 ?g planned for Cohort 4. AIM will continue to provide interim updates on the clinical trial.Shares up 2.3% premarket.In early April, the company advanced the Phase 1 study into Cohort 2 from 1.

For further details see:

AIM Immunotech advances Phase 1 Ampligen study in COVID-19; reports no serious adverse events